Delcath Systems (NASDAQ:DCTH) Price Target Cut to $19.00

Delcath Systems (NASDAQ:DCTHGet Rating) had its price objective reduced by BTIG Research to $19.00 in a research note issued on Tuesday, Stock Target Advisor reports.

A number of other equities research analysts have also weighed in on DCTH. StockNews.com initiated coverage on shares of Delcath Systems in a report on Sunday. They set a “sell” rating on the stock. HC Wainwright decreased their target price on shares of Delcath Systems from $25.00 to $19.00 and set a “buy” rating for the company in a research report on Wednesday, August 10th.

Delcath Systems Price Performance

Shares of DCTH opened at $2.80 on Tuesday. The firm has a market capitalization of $24.07 million, a PE ratio of -0.74 and a beta of 0.92. The company has a debt-to-equity ratio of 2.55, a current ratio of 1.28 and a quick ratio of 1.15. Delcath Systems has a 1-year low of $2.34 and a 1-year high of $10.24. The company’s fifty day moving average price is $3.18 and its 200-day moving average price is $3.93.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Millennium Management LLC acquired a new position in shares of Delcath Systems in the second quarter worth about $40,000. Dimensional Fund Advisors LP acquired a new position in shares of Delcath Systems in the first quarter worth about $75,000. CI Investments Inc. acquired a new position in shares of Delcath Systems in the first quarter worth about $559,000. Cibc World Market Inc. raised its position in shares of Delcath Systems by 4.0% in the first quarter. Cibc World Market Inc. now owns 88,751 shares of the company’s stock worth $568,000 after acquiring an additional 3,432 shares during the period. Finally, Vanguard Group Inc. raised its position in shares of Delcath Systems by 5.7% in the first quarter. Vanguard Group Inc. now owns 360,900 shares of the company’s stock worth $2,309,000 after acquiring an additional 19,605 shares during the period. 26.18% of the stock is currently owned by institutional investors and hedge funds.

Delcath Systems Company Profile

(Get Rating)

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Recommended Stories

Stock Target Advisor logo

Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.